Sana Biotechnology, Inc. (NASDAQ:SANA) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Sana Biotechnology, Inc. (NASDAQ:SANA) have earned a consensus recommendation of “Moderate Buy” from the nine analysts that are currently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation and eight have assigned a buy recommendation to the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $8.1429.

Several analysts recently weighed in on SANA shares. HC Wainwright dropped their price objective on Sana Biotechnology from $11.00 to $9.00 and set a “buy” rating for the company in a research report on Friday, November 7th. Bank of America increased their target price on shares of Sana Biotechnology from $6.00 to $7.00 and gave the stock a “buy” rating in a report on Tuesday. JMP Securities set a $8.00 price target on shares of Sana Biotechnology in a report on Thursday, October 30th. Citigroup reissued an “outperform” rating on shares of Sana Biotechnology in a research note on Thursday, October 30th. Finally, Citizens Jmp boosted their target price on shares of Sana Biotechnology from $5.00 to $8.00 and gave the stock a “market outperform” rating in a research note on Thursday, October 30th.

Sana Biotechnology Trading Up 8.5%

NASDAQ SANA opened at $4.73 on Thursday. The firm’s 50 day simple moving average is $4.28 and its 200 day simple moving average is $3.99. The firm has a market capitalization of $1.26 billion, a price-to-earnings ratio of -4.88 and a beta of 1.96. Sana Biotechnology has a 1 year low of $1.26 and a 1 year high of $7.30.

Sana Biotechnology (NASDAQ:SANA) last announced its quarterly earnings data on Thursday, November 6th. The company reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.18) by $0.03. On average, equities research analysts forecast that Sana Biotechnology will post -1.16 earnings per share for the current year.

Hedge Funds Weigh In On Sana Biotechnology

Large investors have recently bought and sold shares of the company. Wealth Enhancement Advisory Services LLC grew its holdings in shares of Sana Biotechnology by 4.0% during the third quarter. Wealth Enhancement Advisory Services LLC now owns 52,872 shares of the company’s stock worth $188,000 after purchasing an additional 2,023 shares during the last quarter. Creative Planning grew its holdings in Sana Biotechnology by 5.3% during the 3rd quarter. Creative Planning now owns 54,177 shares of the company’s stock worth $192,000 after acquiring an additional 2,719 shares during the last quarter. Savant Capital LLC grew its holdings in Sana Biotechnology by 5.6% during the 3rd quarter. Savant Capital LLC now owns 66,414 shares of the company’s stock worth $236,000 after acquiring an additional 3,500 shares during the last quarter. Viewpoint Capital Management LLC increased its position in Sana Biotechnology by 19.1% in the 2nd quarter. Viewpoint Capital Management LLC now owns 28,045 shares of the company’s stock valued at $77,000 after acquiring an additional 4,500 shares during the period. Finally, Captrust Financial Advisors raised its stake in shares of Sana Biotechnology by 43.8% during the second quarter. Captrust Financial Advisors now owns 15,793 shares of the company’s stock valued at $43,000 after acquiring an additional 4,807 shares during the last quarter. 88.23% of the stock is currently owned by institutional investors.

About Sana Biotechnology

Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.

The company’s core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.